
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Amgen Inc
Deal Size : $65.0 million
Deal Type : Acquisition
Details : The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser, or freeze dryer, that can be used for both Horizon’s commercial medicines, including its rare disease biologics TEPEZZA, KRYSTEXXA and UPLIZNA and ...
Product Name : Tepezza
Product Type : Antibody, Unconjugated
Upfront Cash : $65.0 million
June 17, 2021
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Amgen Inc
Deal Size : $65.0 million
Deal Type : Acquisition
